Live from ACCC

At the recent ACCC Business Summit, Carevive made a significant impression with their session on engaging patients and evaluating clinical cancer programs. Rebekkah Schear and Robin Richardson from UT Austin Dell Medical School Cancer Institute shared their takeaways and the positive reception they received during and after the session.

Engaging Patients and Evaluating Clinical Cancer Programs:

Carevive’s methods of engaging patients and educating them on important aspects of their care resonated with the audience. The session highlighted the need for comprehensive evaluation of clinical cancer programs, going beyond traditional metrics like survival and ED visits. Attendees were eager to learn more about measuring quality of life, patient experience, and provider experience. Carevive’s chart abstraction tool emerged as a valuable resource for capturing and analyzing data.

Interest in Data Sources and Tools:

Attendees were particularly interested in the sources of data used in evaluations and the tools employed to capture it. Carevive’s emphasis on data-driven process improvement and better outcomes struck a chord with the audience. Many expressed curiosity about the tools Carevive developed and their effectiveness.

Recent Episodes

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…